AlanKSearsMD

PubMed

• 23 citations
  Cancer vaccines: should we be targeting patients with less aggressive disease?
  Diane F. Hale, G. Travis Clifton, Alan K. Sears, Timothy J. Vreeland, Nathan M. Shumway, George E. Peoples, Elizabeth A. Mittendorf> ;Expert Review of Vaccines. 2012 Jun 1
• 124 citations
  Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Grou...
  Elizabeth A. Mittendorf, Guy T. Clifton, Kevin S. Clive, Ritesh Patil, Linda C. Benavides, Jeremy D. Gates, Alan K. Sears, Alexander Stojadinovic, Sathibalan Ponniah, ...> ;Cancer. 2012 May 15
• 34 citations
  AE37: a novel T-cell-eliciting vaccine for breast cancer
  Alan K. Sears, Sonia A. Perez, Guy T. Clifton, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Nathan M. Shumway, David C. Van Echo, M. G. Carmichael, Sathibalan ...> ;Expert Opinion on Biological Therapy. 2011 Oct 6
• 11 citations
  Folate receptor α: a storied past and promising future in immunotherapy
  Guy T. Clifton, Alan K. Sears, Kevin S. Clive, Elizabeth A. Mittendorf, C. G. Ioannides, Sathibalan Ponniah, George E. Peoples, Holmes, J. P., Jarrod P. Holmes> ;Human Vaccines. 2011 Feb 1
• 18 citations
  Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
  Linda C. Benavides, Alan K. Sears, Jeremy D. Gates, Guy T. Clifton, Kevin S. Clive, Mark G. Carmichael, Elizabeth A. Mittendorf, Sathibalan Ponniah, George E. Peoples,...> ;Expert Review of Vaccines. 2011 Feb 1
• 31 citations
  Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
  Jeremy D. Gates, Guy T. Clifton, Linda C. Benavides, Alan K. Sears, Mark G. Carmichael, Matthew T. Hueman, Yusuf Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, St...> ;Vaccine. 2010 Nov 3
• Join now to see all